Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Provided By GlobeNewswire
Last update: Oct 30, 2024
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -
Read more at globenewswire.com3.02
-0.68 (-18.38%)
Find more stocks in the Stock Screener
CRDF Latest News and Analysis
2 days ago - ChartmillTop movers in Tuesday's after hours sessionWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
